Efifcacy of thalidomide combined with VAD in treatment of Elderly multiple myeloma and its adverse reactions
- VernacularTitle:沙利度胺联合VAD治疗老年多发性骨髓瘤患者的临床疗效及不良反应探讨
- Author:
Shuang HUI
;
Bo WANG
;
Yuan WANG
;
Wenlian WANG
;
Hongming HUANG
- Publication Type:Journal Article
- Keywords:
thalidomide;
VAD program;
multiple myeloma
- From:
Chinese Journal of Biochemical Pharmaceutics
2014;(2):90-91,94
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efifcacy of thalidomide combined with VAD in treatment of elderly multiple myeloma(MM). Methods 76 cases of elderly MM were randomly divided into two groups, control group (n=38) were treated with VAD alone while the observation group (n=38) were treated with thalidomide and VAD. Clinical efifcacy and adverse reactions in two groups were compared. Results The total effective rate in observation group was 84.21%, which was signiifcantly higher than 55.26%in control group (P<0.05). After treatment, the M protein, myeloma cells andβ2-microglobulin in observation group were (20.77±4.15)×10-2μg/mL, (12.84±2.85)×10-2μg/mL and (2.48±0.53)μg/mL, which were signiifcantly lower than before treatment and control group(P<0.05). Hemoglobin in observation group was (108.83±5.81) g/L, which was signiifcantly higher than before treatment and control group(P<0.05). The adverse reactions were nausea, vomiting, drowsiness, constipation, infection and rash and so on in two groups after treatment, and there was no signiifcant difference between two groups. Conclusion Thalidomide combined with VAD regimen has a better effect in treatment of elderly multiple myeloma than single VAD, has less adverse reactions and well tolerated.
